Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Relating Experienced To Recalled breathlessness Observational (RETRO) study: a prospective study using a mobile phone application.

Sandberg J, Lansing R, Anderberg P, Currow D, Sundh J, Ahmadi Z, Palmqvist S, Ekström M.

BMJ Open Respir Res. 2019 Feb 12;6(1):e000370. doi: 10.1136/bmjresp-2018-000370. eCollection 2019.

2.

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly.

Hahn A, Strandberg TO, Stomrud E, Nilsson M, van Westen D, Palmqvist S, Ossenkoppele R, Hansson O.

Cereb Cortex. 2019 Mar 16. pii: bhz020. doi: 10.1093/cercor/bhz020. [Epub ahead of print]

3.

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.

Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, Palmqvist S, Hansson O.

Neurology. 2019 Feb 5;92(6):e601-e612. doi: 10.1212/WNL.0000000000006875. Epub 2019 Jan 9.

4.

Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study.

Voevodskaya O, Poulakis K, Sundgren P, van Westen D, Palmqvist S, Wahlund LO, Stomrud E, Hansson O, Westman E; Swedish BioFINDER Study Group.

Neurology. 2019 Jan 4. pii: 10.1212/WNL.0000000000006852. doi: 10.1212/WNL.0000000000006852. [Epub ahead of print]

5.

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms.

Palmqvist S, Insel PS, Zetterberg H, Blennow K, Brix B, Stomrud E; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFINDER study, Mattsson N, Hansson O.

Alzheimers Dement. 2019 Feb;15(2):194-204. doi: 10.1016/j.jalz.2018.08.014. Epub 2018 Oct 23.

6.

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.

Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, Palmqvist S, Mattsson N, Janelidze S, Santillo A, Ohlsson T, Jögi J, Tsai R, La Joie R, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, Choi JY, Ryu YH, Lyoo CH, Hansson O.

JAMA. 2018 Sep 18;320(11):1151-1162. doi: 10.1001/jama.2018.12917.

7.

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease.

Mattsson N, Eriksson O, Lindberg O, Schöll M, Lampinen B, Nilsson M, Insel PS, Lautner R, Strandberg O, van Westen D, Zetterberg H, Blennow K, Palmqvist S, Stomrud E, Hansson O.

Neurobiol Aging. 2018 Nov;71:81-90. doi: 10.1016/j.neurobiolaging.2018.07.003. Epub 2018 Jul 11.

PMID:
30107289
8.

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study.

Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, Jögi J, Palmqvist S, Stomrud E, Hansson O.

Alzheimers Res Ther. 2018 Aug 7;10(1):77. doi: 10.1186/s13195-018-0403-x.

9.

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.

Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K, Hansson O.

Neurology. 2018 Aug 28;91(9):e867-e877. doi: 10.1212/WNL.0000000000006082. Epub 2018 Jul 27.

10.

Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.

Mattsson N, Smith R, Strandberg O, Palmqvist S, Schöll M, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Blennow K, Jögi J, Hansson O.

Neurology. 2018 Jan 30;90(5):e388-e395. doi: 10.1212/WNL.0000000000004887. Epub 2018 Jan 10.

11.

Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages.

Pereira JB, Strandberg TO, Palmqvist S, Volpe G, van Westen D, Westman E, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

Cereb Cortex. 2018 Jan 1;28(1):340-349. doi: 10.1093/cercor/bhx294.

12.

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity.

Palmqvist S, Schöll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O.

Nat Commun. 2017 Oct 31;8(1):1214. doi: 10.1038/s41467-017-01150-x.

13.

Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.

Schöll M, Ossenkoppele R, Strandberg O, Palmqvist S; Swedish BioFINDER study, Jögi J, Ohlsson T, Smith R, Hansson O.

Brain. 2017 Sep 1;140(9):2286-2294. doi: 10.1093/brain/awx171.

PMID:
29050382
14.

Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and Aβ Pathology in Non-demented Individuals.

Lindberg O, Mårtensson G, Stomrud E, Palmqvist S, Wahlund LO, Westman E, Hansson O.

Front Aging Neurosci. 2017 Sep 20;9:306. doi: 10.3389/fnagi.2017.00306. eCollection 2017.

15.

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.

Mattsson N, Schöll M, Strandberg O, Smith R, Palmqvist S, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Jögi J, Blennow K, Hansson O.

EMBO Mol Med. 2017 Sep;9(9):1212-1223. doi: 10.15252/emmm.201707809.

16.

Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people.

Hansson O, Palmqvist S, Ljung H, Cronberg T, van Westen D, Smith R.

Alzheimers Dement. 2018 Jan;14(1):54-61. doi: 10.1016/j.jalz.2017.06.2265. Epub 2017 Jul 15.

17.

The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort.

Borland E, Nägga K, Nilsson PM, Minthon L, Nilsson ED, Palmqvist S.

J Alzheimers Dis. 2017;59(3):893-901. doi: 10.3233/JAD-170203.

18.

Plasma tau in Alzheimer disease.

Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K; ADNI Investigators.

Neurology. 2016 Oct 25;87(17):1827-1835. Epub 2016 Sep 30.

19.

Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information.

Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, Mattsson N.

Alzheimers Dement (Amst). 2016 Aug 3;4:76-84. eCollection 2016.

20.

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.

Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, Blennow K, Hansson O; Alzheimer's Disease Neuroimaging Initiative.

EMBO Mol Med. 2016 Oct 4;8(10):1184-1196. doi: 10.15252/emmm.201606540. Print 2016 Oct.

21.

Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?

Palmqvist S, Mattsson N, Hansson O.

Brain. 2016 Nov 1;139(11):e61. doi: 10.1093/brain/aww169. No abstract available.

PMID:
27383527
22.

Plasma β-amyloid in Alzheimer's disease and vascular disease.

Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D, Tan Hehir CA, Baker D, Blennow K, Hansson O.

Sci Rep. 2016 May 31;6:26801. doi: 10.1038/srep26801.

23.

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.

Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, van Westen D, Stomrud E, Minthon L, Blennow K; Swedish BioFINDER study group, Hansson O.

Ann Clin Transl Neurol. 2016 Jan 1;3(3):154-65. doi: 10.1002/acn3.274. eCollection 2016 Mar.

24.

The prevalence and predictive value of the SLC30A8 R325W polymorphism and zinc transporter 8 autoantibodies in the development of GDM and postpartum type 1 diabetes.

Dereke J, Palmqvist S, Nilsson C, Landin-Olsson M, Hillman M.

Endocrine. 2016 Sep;53(3):740-6. doi: 10.1007/s12020-016-0932-7. Epub 2016 Mar 22.

PMID:
27003436
25.

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis.

Mattsson N, Insel PS, Palmqvist S, Stomrud E, van Westen D, Minthon L, Zetterberg H, Blennow K, Hansson O.

Nat Commun. 2016 Mar 7;7:10918. doi: 10.1038/ncomms10918.

26.

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.

Palmqvist S, Mattsson N, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2016 Apr;139(Pt 4):1226-36. doi: 10.1093/brain/aww015. Epub 2016 Mar 2.

27.

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.

Palmqvist S, Zetterberg H, Mattsson N, Johansson P; Alzheimer's Disease Neuroimaging Initiative, Minthon L, Blennow K, Olsson M, Hansson O; Swedish BioFINDER Study Group.

Neurology. 2015 Oct 6;85(14):1240-9. doi: 10.1212/WNL.0000000000001991. Epub 2015 Sep 9.

28.

Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study.

Nägga K, Wattmo C, Zhang Y, Wahlund LO, Palmqvist S.

Alzheimers Res Ther. 2014 Jul 7;6(4):41. doi: 10.1186/alzrt271. eCollection 2014.

29.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
30.

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.

JAMA Neurol. 2014 Oct;71(10):1282-9. doi: 10.1001/jamaneurol.2014.1358.

PMID:
25155658
31.

A Quick Test of Cognitive Speed: norm-referenced criteria for 121 Italian adults aged 45 to 90 years.

Petrazzuoli F, Palmqvist S, Thulesius H, Buono N, Pirrotta E, Cuffari A, Cambielli M, D'Urso M, Farinaro C, Chiumeo F, Marsala V, Wiig EH.

Int Psychogeriatr. 2014 May 9:1-8. [Epub ahead of print]

PMID:
24810919
32.

Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination.

Londos E, Hanxsson O, Alm Hirsch I, Janneskog A, Bülow M, Palmqvist S.

BMC Neurol. 2013 Oct 7;13:140. doi: 10.1186/1471-2377-13-140.

33.

Tau pathology and parietal white matter lesions have independent but synergistic effects on early development of Alzheimer's disease.

Hertze J, Palmqvist S, Minthon L, Hansson O.

Dement Geriatr Cogn Dis Extra. 2013 Apr 19;3(1):113-22. doi: 10.1159/000348353. Print 2013 Jan.

34.

Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study.

Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, Londos E, Hansson O.

PLoS One. 2012;7(6):e38639. doi: 10.1371/journal.pone.0038639. Epub 2012 Jun 22.

35.

Association between subcortical lesions and behavioral and psychological symptoms in patients with Alzheimer's disease.

Palmqvist S, Sarwari A, Wattmo C, Bronge L, Zhang Y, Wahlund LO, Nägga K.

Dement Geriatr Cogn Disord. 2011;32(6):417-23. doi: 10.1159/000335778. Epub 2012 Feb 16.

PMID:
22343788
36.

Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative dementia.

Nielsen HM, Palmqvist S, Minthon L, Londos E, Wennström M.

Curr Alzheimer Res. 2012 Mar;9(3):257-66.

PMID:
22191565
37.

A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.

Palmqvist S, Minthon L, Wattmo C, Londos E, Hansson O.

Alzheimers Res Ther. 2010 Oct 15;2(5):29. doi: 10.1186/alzrt53.

38.

Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.

Johansson C, Ballard C, Hansson O, Palmqvist S, Minthon L, Aarsland D, Londos E.

Int J Geriatr Psychiatry. 2011 Feb;26(2):206-13. doi: 10.1002/gps.2516.

PMID:
20665553
39.

[Lewy body dementia--big risk of wrong treatment and death].

Boström F, Palmqvist S, Andersson M, Londos E.

Lakartidningen. 2009 May 13-19;106(20):1374-6. Swedish. No abstract available.

PMID:
19585833
40.

Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests.

Palmqvist S, Hansson O, Minthon L, Londos E.

Int J Geriatr Psychiatry. 2009 Dec;24(12):1405-12. doi: 10.1002/gps.2277.

PMID:
19347836
41.

Changes in attitudes toward desire for implant treatment: a longitudinal study of a middle-aged and older Swedish population.

Narby B, Kronström M, Söderfeldt B, Palmqvist S.

Int J Prosthodont. 2008 Nov-Dec;21(6):481-5.

PMID:
19149061
42.

The usefulness of cube copying for evaluating treatment of Alzheimer's disease.

Palmqvist S, Hansson O, Minthon L, Londos E.

Am J Alzheimers Dis Other Demen. 2008 Oct-Nov;23(5):439-46. doi: 10.1177/1533317508320084.

PMID:
18955723
43.

Prosthodontics and the patient. Part 2: Need becoming demand, demand becoming utilization.

Narby B, Kronström M, Söderfeldt B, Palmqvist S.

Int J Prosthodont. 2007 Mar-Apr;20(2):183-9.

PMID:
17455442
44.

Oral prostheses and oral health-related quality of life: a survey study of an adult Swedish population.

Bagewitz IC, Söderfeldt B, Palmqvist S, Nilner K.

Int J Prosthodont. 2007 Mar-Apr;20(2):132-42.

PMID:
17455432
45.

20-year follow-up of patients receiving high-cost dental care within the Swedish Dental Insurance System: 1977-1978 to 1998-2000.

Petersson K, Pamenius M, Eliasson A, Narby B, Holender F, Palmqvist S, Håkansson J.

Swed Dent J. 2006;30(2):77-86.

PMID:
16878683
46.

Transcriptional regulation of the sbeIIb genes in sorghum (Sorghum bicolor) and barley (Hordeum vulgare): importance of the barley sbeIIb second intron.

Mutisya J, Sun C, Palmqvist S, Baguma Y, Odhiambo B, Jansson C.

J Plant Physiol. 2006 May;163(7):770-80. Epub 2005 Oct 25.

PMID:
16616588
47.

Dimensions of oral health-related quality of life in an adult Swedish population.

Bagewitz IC, Söderfeldt B, Nilner K, Palmqvist S.

Acta Odontol Scand. 2005 Nov;63(6):353-60.

PMID:
16512108
48.

Indications for removable partial dentures: a literature review.

Wöstmann B, Budtz-Jørgensen E, Jepson N, Mushimoto E, Palmqvist S, Sofou A, Owall B.

Int J Prosthodont. 2005 Mar-Apr;18(2):139-45. Review.

PMID:
15889662
49.
50.

The dentist's communicative role in prosthodontic treatment.

Sondell K, Palmqvist S, Söderfeldt B.

Int J Prosthodont. 2004 Nov-Dec;17(6):666-71.

PMID:
15686094

Supplemental Content

Loading ...
Support Center